Literature DB >> 21422798

Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient.

Nirmala Rosseti1, Leonardo Calza, Benedetta Piergentili, Alessandra Cascavilla, Fabio Filippo Trapani, Andrea Berlingeri, Ginevra Marinacci, Luciano Attard, Gabriella Verucchi.   

Abstract

Amiodarone, which has been used since 1967 as an antiarrhythmic drug, gives rise to a variety of cardiac and extracardiac adverse side-effects. Among these, pulmonary toxicity is considered the most frequent and serious extracardiac side-effect, since it may occur in various atypical forms and often limits the drug's clinical use. We encountered a 67-year-old white male patient with suspected amiodarone pneumonitis characterized by multiple lung nodules associated with pleural and pericardial effusion and peripheral neuropathy. Because differential diagnosis with pulmonary infectious diseases may be extremely difficult, the attending physician should therefore bear in mind the possibility of amiodarone pneumonitis whenever the drug is given.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21422798      PMCID: PMC7100449          DOI: 10.1007/bf03324945

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  15 in total

1.  Amiodarone pneumonitis.

Authors:  Jeffrey I Stewart; Rashmi Chawla; Joshua M Lloyd; Gregory C Kane
Journal:  Respir Care       Date:  2008-03       Impact factor: 2.258

2.  Possible association of pneumonitis with amiodarone therapy.

Authors:  H H Rotmensch; M Liron; M Tupilski; S Laniado
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

Review 3.  Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.

Authors:  P T Pollak
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

4.  Frequency, characteristics, and risk factors for amiodarone neurotoxicity.

Authors:  Carolyn F Orr; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2009-07

Review 5.  Amiodarone: guidelines for use and monitoring.

Authors:  Lyle A Siddoway
Journal:  Am Fam Physician       Date:  2003-12-01       Impact factor: 3.292

Review 6.  Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I).

Authors:  W J Martin; E C Rosenow
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

7.  Amiodarone-related pneumonitis.

Authors:  Sheng-Nan Chang; Juey-Jen Hwang; Kuan-Lih Hsu; Chia-Ti Tsai; Ling-Ping Lai; Jiunn-Lee Lin; Chuen-Den Tseng; Fu-Tien Chiang
Journal:  J Formos Med Assoc       Date:  2007-05       Impact factor: 3.282

Review 8.  Amiodarone pulmonary toxicity.

Authors:  Philippe Camus; William J Martin; Edward C Rosenow
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

9.  Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level.

Authors:  Konrad Stadler; Huy Riem Ha; Vincenzo Ciminale; Carlo Spirli; Giulietta Saletti; Marco Schiavon; Daniela Bruttomesso; Laurent Bigler; Ferenc Follath; Andrea Pettenazzo; Aldo Baritussio
Journal:  Am J Respir Cell Mol Biol       Date:  2008-02-28       Impact factor: 6.914

Review 10.  Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.

Authors:  Jonathan P Piccini; Jeffrey S Berger; Christopher M O'Connor
Journal:  Eur Heart J       Date:  2009-03-31       Impact factor: 29.983

View more
  1 in total

1.  Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: A case report and literature review.

Authors:  Amer Hawatmeh; Mohammad Thawabi; Ashraf Jmeian; Hamid Shaaban; Fayez Shamoon
Journal:  J Nat Sci Biol Med       Date:  2017 Jan-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.